Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | STAMBP | O95630 | 1/20 | 0.43 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795758 | 1.00 | RXFP1 (0.49) | RXFP1PPARGALDH1A1KLKB1MAP4K1 | |
| SCHEMBL15328395 | 0.81 | KMT2A (0.48) | RXFP1PPARGALDH1A1KLKB1SMN1; SMN2 | |
| SCHEMBL15733189 | 0.80 | RXFP1 (0.49) | RXFP1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15328281 | 0.80 | S1PR3 (0.48) | RXFP1PPARGALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL15328406 | 0.79 | CFTR (0.45) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL15733248 | 0.77 | RXFP1 (0.50) | RXFP1ALDH1A1SMN1; SMN2KMT2AEGLN1 | |
| SCHEMBL15733302 | 0.76 | L3MBTL1 (0.45) | ALDH1A1SMN1; SMN2MEN1KMT2AEGLN1 | |
| SCHEMBL2130011 | 0.76 | RXFP1 (0.44) | RXFP1KLKB1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15735460 | 0.76 | THRB (0.48) | RXFP1ALDH1A1KLKB1SMN1; SMN2MEN1 | |
| SCHEMBL31038813 | 0.76 | STAT6 (0.49) | RXFP1ALDH1A1TRPV1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925316-A1 | SUBSTITUTED AMINO-ARYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-10-07 | — | — | EP | claimed |
| WO-2014082739-A1 | SUBSTITUTED AMINO-ARYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-06-05 | — | — | WO | claimed |
| US-20140148454-A1 | SUBSTITUTED AMINO-ACRYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-05-29 | — | — | US | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2925316-A1 | SUBSTITUTED AMINO-ARYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014082739-A1 | SUBSTITUTED AMINO-ARYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-06-05 | — | — | WO | disclosed |
| US-20140148454-A1 | SUBSTITUTED AMINO-ACRYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148454-A1 | SUBSTITUTED AMINO-ACRYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148454-A1 | SUBSTITUTED AMINO-ACRYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148454-A1 | SUBSTITUTED AMINO-ACRYLCARBOXAMIDES AS KCNQ2/3 MODULATORS | KCNJ2, KCNQ1, KCNQ2 | RXFP1 3948/4885PPARG 1446/4885ALDH1A1 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.